Literature DB >> 24414183

Severe hypocalcaemia as a cause of seemingly idiopathic bilateral lower limb oedema.

Aaron Karnell Dachuan Hung1.   

Abstract

The existing scientific literature has not drawn a link between severe hypocalcaemia and its role in recalcitrant peripheral oedema. This phenomenon is particularly relevant in oncological and geriatric medicine as bone strengthening but serum calcium-lowering agents such as bisphosphonates and denosumab are used for osteoporosis and/or bone metastasis. This case report, through metastatic prostate cancer in a 66-year-old man with bone metastasis being treated with a monoclonal antibody denosumab, proposes the mechanism of hypocalcaemic oedema as being akin to calcium deprivation such as those induced by calcium channel antagonism. It demonstrates the importance of calcium supplementation as a concurrent treatment while patients are on these osteoclast inhibiting agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24414183      PMCID: PMC3902373          DOI: 10.1136/bcr-2013-201387

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.

Authors:  A Béhar; E Pujade-Lauraine; A Maurel; M D Brun; F F Chauvin; F Feuilhade de Chauvin; D Oulid-Aissa; D Hille
Journal:  Br J Clin Pharmacol       Date:  1997-06       Impact factor: 4.335

2.  Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials.

Authors:  Harikrishna Makani; Sripal Bangalore; Jorge Romero; Nay Htyte; Ronaldo S Berrios; Hetal Makwana; Franz H Messerli
Journal:  J Hypertens       Date:  2011-07       Impact factor: 4.844

3.  Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.

Authors:  Roberto Pedrinelli; Giulia Dell'Omo; Marco Nuti; Alessandra Menegato; Alberto Balbarini; Mario Mariani
Journal:  J Hypertens       Date:  2003-10       Impact factor: 4.844

4.  Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.

Authors:  F Milat; S Goh; L U Gani; C Suriadi; M T Gillespie; P J Fuller; H J Teede; A H Strickland; C A Allan
Journal:  Bone       Date:  2013-04-25       Impact factor: 4.398

Review 5.  Managing peripheral edema in patients with arterial hypertension.

Authors:  Benjamin J Epstein; Mary Ellen Roberts
Journal:  Am J Ther       Date:  2009 Nov-Dec       Impact factor: 2.688

6.  Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

Authors:  Karim Fizazi; Linda Bosserman; Guozhi Gao; Tomas Skacel; Richard Markus
Journal:  J Urol       Date:  2009-06-13       Impact factor: 7.450

7.  Severe hypocalcemia following denosumab injection in a hemodialysis patient.

Authors:  Brendan B McCormick; Janet Davis; Kevin D Burns
Journal:  Am J Kidney Dis       Date:  2012-07-31       Impact factor: 8.860

8.  A single-dose study of denosumab in patients with various degrees of renal impairment.

Authors:  Geoffrey A Block; Henry G Bone; Liang Fang; Edward Lee; Desmond Padhi
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

Review 9.  The role of RANK-ligand inhibition in cancer: the story of denosumab.

Authors:  Daniel Castellano; Juan Manuel Sepulveda; Ignacio García-Escobar; Alfredo Rodriguez-Antolín; Anna Sundlöv; Hernán Cortes-Funes
Journal:  Oncologist       Date:  2011-02-01

10.  Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.

Authors:  Ursa Brown-Glaberman; Alison T Stopeck
Journal:  Biologics       Date:  2012-04-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.